MENU
+Compare
HUMA
Stock ticker: NASDAQ
AS OF
Mar 28 closing price
Price
$1.96
Change
-$0.05 (-2.49%)
Capitalization
301.19M

HUMA Humacyte Forecast, Technical & Fundamental Analysis

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine... Show more

HUMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for HUMA with price predictions
Mar 27, 2025

HUMA's RSI Indicator sits in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HUMA advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .

HUMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HUMA as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HUMA turned negative on March 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 32 similar instances when the indicator turned negative. In of the 32 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HUMA entered a downward trend on March 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (30.303) is normal, around the industry mean (14.047). P/E Ratio (0.000) is within average values for comparable stocks, (66.086). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.907). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (239.969).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. HUMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
HUMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

HUMA is expected to report earnings to fall 23.82% to -25 cents per share on March 28

Humacyte HUMA Stock Earnings Reports
Q4'24
Est.
$-0.25
Q3'24
Missed
by $0.08
Q2'24
Missed
by $0.24
Q1'24
Missed
by $0.06
Q4'23
Est.
$-0.24
The last earnings report on November 08 showed earnings per share of -33 cents, missing the estimate of -25 cents. With 11.97M shares outstanding, the current market capitalization sits at 301.19M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2525 East North Carolina Highway 54
Phone
+1 919 313-9633
Employees
185
Web
https://www.humacyte.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IUAEX26.15N/A
N/A
JPMorgan International Focus A
LGGAX63.07N/A
N/A
ClearBridge International Growth A
GCSLX18.96N/A
N/A
Pioneer Global Sustainable Equity C
VRSCX21.41N/A
N/A
Voya SmallCap Opportunities Port R6
WCFEX14.27N/A
N/A
WCM Focused Emerging Mkts Ex Chn Inv

HUMA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HUMA has been loosely correlated with RXRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if HUMA jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HUMA
1D Price
Change %
HUMA100%
+0.50%
RXRX - HUMA
40%
Loosely correlated
-3.24%
KYMR - HUMA
38%
Loosely correlated
-0.63%
CCCC - HUMA
36%
Loosely correlated
-0.54%
XERS - HUMA
35%
Loosely correlated
-1.40%
AURA - HUMA
35%
Loosely correlated
-0.83%
More